MedNewsWeek

Excited about what is to come. Stay tuned. Lots of amazing initiatives in store. Continue to follow @MedNewsWeek on all of our platforms.

WATCH 👀: @MattGalsky of @TischCancer discusses data from the phase 3 KEYNOTE-B15 trial which looked at neoadjuvant and adjuvant EV plus pembrolizumab in MIBC. See the whole video here 📽️: hubs.li/Q047QVwg0 #blcsm #oncology

In the non-HLA-A*02 arm of the FLAMINGO-1 trial, breast recurrence rates were less than 1% following treatment with GLSI-100. GLSI is a novel immunotherapy that was administered intradermally every month for the first 6 months, followed by every 6 months for the next 2.5 years. hubs.li/Q047NlTl0 #bcsm #BreastCancer #Oncology

Albert, great discussion with a powerhouse prostate cancer panel—Dr. Maha Hussain, Dr. Sandy Srinivas, Dr. Dan Petrylak, Dr. Ulka Vaishampayan, and Dr. Ben Maughan 👏 We learned so much from your case discussion at #MatosGU26. This is how we all get better. @AJangMD @PGrivasMDPhD @mecmededucation 💡 💥 Loved this moment. Great job Albert! #Oncology #MedEd #ProstateCancer @DanielPetrylak @sandysrimd @DrVaishampayan @maughanonc @oncodaily @urotoday @Larvol

We presented exploratory analysis from pts with PR/CR on EV-302 trial #ASCOGU26. Poster Walk @Dr_Aggen 🔹 CR -30% w/ EVP vs 15% w/chemo 🔹 Median time to PR/CR w/ EVP -2.1 mo 🔹 PFS OS maintained at 24 mos PR/CR 🔹 20% pts who had CR on EVP converted from initial PR at median 4.6 mo These data reiterate that it's imp to continue Tx with dose reductions/breaks when necessary. @tompowles1 @Uromigos @CleClinicMD @OncoAlert @OncBrothers

1/5 🧵 Three phase III trials evaluated adding systemic IO to intravesical BCG in BCG-naïve high-risk NMIBC: • CREST – sasanlimab • POTOMAC – durvalumab • ALBAN – atezolizumab CREST and POTOMAC both met their primary endpoints (HR 0.68). ALBAN was neutral (HR 0.98). (Many valid reasons for the negative results in ALBAN @MRoupret @y_loriot but truth remains: there is a signal for IO)

💡What is the effect of GLP-1 medications on bladder cancer therapy and overall survival? Dr. Arnab Basu @MayoClinic introduces his new GU Fellow’s thought provoking research. Great job @TayoAdeoyeMD #OncLiveTakeOver @CParkMD @arnabguonc @ZakhariaYousef @GIcancerDoc @parrysingh @yekeduz_emre @DrYukselUrun @crisbergerot @PGrivasMDPhD @BladderCancerUS @WorldBladderCan

🧬🩺 Can local immune modulation rescue encapsulated cell therapies? A new study in Science Translational Medicine explores whether targeting innate immunity can improve outcomes for immunoisolated β-cell transplants in primates. 🔬 Strategy: Alginate spheres co-encapsulating β cells + slow-release crystals of a CSF1R inhibitor (GW2580) to blunt the foreign body response (FBR). 📊 Key findings: 🐭 In immunocompetent diabetic mice: • Human stem cell–derived β cells maintained glycemic control for 1 year 🐒 In nonhuman primates (NHPs): • Allogeneic β cells remained viable and glucose-responsive at 1 month • No systemic immunosuppression required 🚫 But… • Xenogeneic human β cells failed in NHPs • Marked adaptive immune activation (↑ CD4+ T cells, CD19+ B cells, APC programs, MHC-II expression) • Upregulation of chemokines CCL17, CCL22, CXCL13 🧠 Interpretation: Localized CSF1R inhibition appears sufficient to control innate-driven fibrosis and rejection in allogeneic settings, but xenogeneic sources in higher-order species trigger robust adaptive immunity that overwhelms this strategy. ⚖️ Takeaway: Innate immune targeting may unlock encapsulated allogeneic cell therapies—yet xenotransplantation likely requires additional adaptive immune modulation. science.org/doi/10.1126/sc…

🌟Introducing the advisory board for ASCO AI in Oncology: 🔹Editor-in-Chief Ravi B. Parikh, MD, MPP, FACP @ravi_b_parikh 🔹Kenneth L. Kehl, MD, MPH 🔹Danielle S. Bitterman, MD @dbittermanmd 🔹Travis Zack, MD, PhD 🔹Jame Abraham, MD, FACP @jamecancerdoc ascoai.org/editorial-advi…

Congratulations to the Indiana team with @JenniferKingMD and @nabiladra presenting cabozantinib in refractory GCT, CBR 43%, very tough area to make progress, glad to see multiple MOAs advancing to try and bring better options for this patient population

#ASCOGU26 🧵3/5: NIAGARA utDNA data — first-ever utDNA with clinical correlation in a phase 3 periop trial. - Combined utDNA+ctDNA post-neoadjuvant/pre-cystectomy identified the highest 24-mo EFS group. - utDNA tracks residual non-invasive disease; ctDNA tracks invasive disease.

It’s all about the bladder! 🚽✨ Another epic day with my CCF crew — brains, banter, and big bladder energy! Let’s gooo! 🔥 @LauraBukavinaMD @cjweight @RAlaghehbandan @CleClinicUro @CleClinicUroRes @JacobKnorr10

As we wrap a whirlwind of data in bladder cancer at #GU26, wishing everyone safe travels home. Rest up - London and #EAU26 are just around the corner! I'm especially excited to once again lead the "Common Problems and Controversies in Bladder Cancer: Rapid-fire Debates." Friday 13 March 10:45 - 12:15 We’ve designed this session to cut through the noise - no long lectures - just leading experts, opposing viewpoints, and the direct clinical insights you need for daily practice. It remains one of the most anticipated highlights of the meeting for a reason!

💡✨ @ASCO #GU26 @DrChoueiri

Loved catching up with Emre Yekeduz about our upcoming research @ASCO #GU26 Bladder cancer research is accelerating- rational combinations, and maybe even bispecifics targeting PD-1 + VEGF in GU cancers🧬 The field is evolving fast. 🚀 @yekeduz_emre @DrYukselUrun @nataliagandur @crisbergerot @Stefani19753108 @DanaFarber_GU @DrChoueiri

⭐️Progress in oncology is built in moments of shared curiosity. Dinner meeting with Oliver Sartor @sartor_oliver my VISION co-PI and pioneer of PSMA radioligand therapy, discussing how Lutetium-177 is becoming the Model T of radioligand therapy — the first scalable platform for precision systemic radiation in prostate cancer ⚛️🚀 Walking back, we ran into Jonathan Rosenberg (@DrRosenbergMSK ), my EV-301 co-PI and global leader in antibody–drug conjugate development, he discussed Enfortumab vedotin, KEYNOTE-B15, and the convergence of targeted payload therapies 🎯 Not different drugs. Different chapters of the same scientific story 📖 Radioligands. Antibody–drug conjugates. Precision targeting is reshaping cancer therapy 🌍 The future of oncology will be written in better precision development — and in the patients who benefit from it. Where do you think precision oncology goes next? @tompowles1 @DrChoueiri @neerajaiims @PGrivasMDPhD @montypal @shilpaonc @DrYukselUrun @crisbergerot @alantanmd @Stefani19753108 @arnabguonc @Dr_Aggen #serendipity ✨ #GU26 @ASCO @urotoday @oncodaily @OncLive

At #GU26 a tremendous overview of optimal trial design by @PavlosMsaouel. Pavlos has repeatedly shown that even in very rare cancers, optimally designed studies can rapidly led to practice changing findings. A visionary in our field.

✌️ PEACE-3 is a true OS-positive trial. Enzalutamide + radium-223 beats enzalutamide alone in bone-dominant mCRPC. ✅ HR 0.76 (24% ↓ death risk) ~6 month median OS gain. ✅ Median OS: 32.6 → 38.2 months (~6-month gain!) 💥 1️⃣ Manageable safety (↑ hypertension/fractures) 2️⃣ Radiopharm + ARPI = proven survival boost 3️⃣ Debate: Where does it fit post-ARPI era? 4️⃣ Trials like ARCHES, ENZAMET, TITAN, ARANOTE, and ARASENS have made ARPIs standard in mHSPC. @oncodaily @urotoday @PCFnews @ZEROCancer #ProstateCancer #Oncology #pcsm

⭐️Follow along today as @CParkMD of @Norton_Health and Advisory Dean/Clinical Professor at @uofl takes us along at @ASCO #GU26 .

Grateful to everyone who joined the discussion.

We’re proud to see Dr. Leyfman deliver 2 oral presentations this week focused on AI innovation and advancing global oncology education. This work reflects the core of MedNews Week’s mission — expanding access, elevating evidence, and reducing inequities in cancer care.